183 related articles for article (PubMed ID: 35545838)
1. A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer.
Lin X; Lin L; Wu J; Jiang W; Wu J; Yang J; Chen C
Thorac Cancer; 2022 Jun; 13(11):1691-1702. PubMed ID: 35545838
[TBL] [Abstract][Full Text] [Related]
2. Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer.
Zhang L; Xie G; Xiao X; Cheng C
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3835-3846. PubMed ID: 35997823
[TBL] [Abstract][Full Text] [Related]
3. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer.
Yang G; Zhou D; Dai Y; Li Y; Wu J; Liu Q; Deng X
Thorac Cancer; 2022 Nov; 13(21):2941-2950. PubMed ID: 36117149
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy.
Lv H; Wang T; Ma F; Zhang K; Gao T; Pei R; Zhang Y
Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147520
[TBL] [Abstract][Full Text] [Related]
5. Biomimetic exosomal vesicles loaded with siRNA improves antitumor immune responses by inhibiting the secretion of tumor-derived exosome PD-L1.
Zhang C; Wu Q; Gong Y; Qin Q; Han Q; Cheng Z; Yan Z
Int Immunopharmacol; 2024 Mar; 129():111659. PubMed ID: 38350356
[TBL] [Abstract][Full Text] [Related]
6. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer.
Liu B; Cao W; Qiao G; Yao S; Pan S; Wang L; Yue C; Ma L; Liu Y; Cui D
Acta Biomater; 2019 Nov; 99():307-319. PubMed ID: 31513911
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
9. Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer.
Li Z; Yang L; Wang H; Binzel DW; Williams TM; Guo P
Nucleic Acid Ther; 2021 Oct; 31(5):364-374. PubMed ID: 33999716
[TBL] [Abstract][Full Text] [Related]
10. Effective delivery of anti-PD-L1 siRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines.
Rajabinejad M; Valadan R; Tehrani M; Najafi A; Negarandeh R; Saeedi M; Asgarian-Omran H
Med Oncol; 2024 May; 41(6):149. PubMed ID: 38739199
[TBL] [Abstract][Full Text] [Related]
11. Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.
Yang T; Fogarty B; LaForge B; Aziz S; Pham T; Lai L; Bai S
AAPS J; 2017 Mar; 19(2):475-486. PubMed ID: 27882487
[TBL] [Abstract][Full Text] [Related]
12. Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions.
Thiramanas R; Li M; Jiang S; Landfester K; Mailänder V
Cells; 2020 Sep; 9(9):. PubMed ID: 32906726
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
Luo X; Peng X; Hou J; Wu S; Shen J; Wang L
Int J Nanomedicine; 2017; 12():5331-5343. PubMed ID: 28794626
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence Super-Resolution Imaging Chip for Gene Silencing Exosomes.
Yin G; Qi T; Wei J; Wang T; Wang Z; Cui Y; Zong S
Sensors (Basel); 2023 Dec; 24(1):. PubMed ID: 38203034
[TBL] [Abstract][Full Text] [Related]
16. PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer.
Chen Z; Krishnamachary B; Mironchik Y; Ray Banerjee S; Pomper MG; Bhujwalla ZM
Nanoscale; 2022 Oct; 14(38):14014-14022. PubMed ID: 36093754
[TBL] [Abstract][Full Text] [Related]
17. Exosome as a Natural Gene Delivery Vector for Cancer Treatment.
Pofali P; Mondal A; Londhe V
Curr Cancer Drug Targets; 2020; 20(11):821-830. PubMed ID: 32972340
[TBL] [Abstract][Full Text] [Related]
18. Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery.
Lu M; Zhao X; Xing H; Liu H; Lang L; Yang T; Xun Z; Wang D; Ding P
Acta Biomater; 2019 Sep; 96():517-536. PubMed ID: 31284098
[TBL] [Abstract][Full Text] [Related]
19. Exosome-Modified Tissue Engineered Blood Vessel for Endothelial Progenitor Cell Capture and Targeted siRNA Delivery.
Chen W; Yang M; Bai J; Li X; Kong X; Gao Y; Bi L; Xiao L; Shi B
Macromol Biosci; 2018 Feb; 18(2):. PubMed ID: 29205878
[TBL] [Abstract][Full Text] [Related]
20. Exosome-mediated delivery of siRNA in vitro and in vivo.
El-Andaloussi S; Lee Y; Lakhal-Littleton S; Li J; Seow Y; Gardiner C; Alvarez-Erviti L; Sargent IL; Wood MJ
Nat Protoc; 2012 Dec; 7(12):2112-26. PubMed ID: 23154783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
